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 First study on in vitro inhalation bioaccessibility of organics from house dust 4 
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Abstract  26 
Phthalate esters (PEs) are plasticiser additives imparting durability, elasticity and flexibility 27 
to consumer products. The low migration stability of PEs along with their ubiquitous 28 
character and adverse health effects to humans and especially children has resulted in their 29 
classification as major indoor contaminants.  This study assesses inhalation exposure to PEs 30 
via indoor dust using an  in vitro inhalation bioaccessibility test (i.e. uptake) for of dimethyl 31 
phthalate (DMP), diethyl phthalate (DEP) and di-(2-ethylhexyl) phthalate (DEHP) and the 32 
alternative non phthalate plasticisers bis(2-ethylhexyl) terephthalate (DEHT) and 33 
cyclohexane-1,2-dicarboxylic acid diisononyl ester (DINCH), exposure. Using artificial lung 34 
fluids, which mimicktwo distinctively different pulmonary environments, namely artificial 35 
lysosomal fluid (ALF, pH = 4.5) representing the fluid that inhaled particles would contact 36 
after phagocytosis by alveolar and interstitial macrophages within the lung and Gamble’s 37 
solution (pH = 7.4), the fluid for deep dust deposition within the pulmonary environment. 38 
Low molecular weight (MW) PEs such as DMP and DEP were highly bioaccessible (> 75 %) 39 
in both artificial pulmonary media, whereas highly hydrophobic compounds such as DEHP, 40 
DINCH and DEHT were < 5 % bioaccessible via the lung. Our findings show that the in vitro 41 
pulmonary uptake of PEs is primarily governed by their hydrophobicity and water solubility, 42 
highlighting thus the need for the establishment of a unified and biologically relevant 43 
inhalation bioaccessibility test format, employed within the risk assessment framework for 44 
volatile and semi-volatile organic pollutants.  45 
 46 
Keywords: bioaccessibility, inhalation, phthalate esters, indoor dust, artificial lysosomal 47 
fluid, DINCH   48 
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Introduction 50 
Phthalate esters (PEs) are plasticiser additives enhancing durability, elasticity and flexibility 51 
in consumer and polymeric products 1. Low molecular weight (LMW) PEs such as dimethyl 52 
phthalate (DMP) and diethyl phthalate (DEP) are added as synthetic stabilisers to industrial 53 
solvents and personal care products they are also used as colouring or fragrance additives 2,3. 54 
High MW (HMW) PEs such as di-(2-ethylhexyl) phthalate (DEHP) and di-iso-nonyl 55 
phthalate (DiNP) are primarily used in polyvinyl chloride (PVC) products including floor 56 
polishing, wall coatings, children’s toys, medical products and food packaging 4–6. Their low 57 
migration stability and vapour pressure influence PE release to the indoor environment, 58 
resulting in their classification as major indoor organic contaminants 7,8. Consequently, 59 
considerably high levels of PEs have been found in indoor dust worldwide 5,9–13.  60 
Human exposure to PEs in the indoor environment is a phenomenon of growing concern due 61 
to the potentially adverse health effects of PEs such as DEHP, di-n-butyl phthalate (DnBP) 62 
and di-iso-butyl phthalate (DiBP) in adults, such as disrupted endocrine and thyroid 63 
homeostasis, reduced fertility and reproduction 3,14,15. Hence, the US and the EU have partly 64 
restricted the use of DiBP, DnBP, and DEHP in toys and childcare products 16,17. Such 65 
actions paved the way for the introduction of less toxic, non-phthalate substitutes (i.e. 66 
alternative plasticisers) in consumer products in the early 2000s, such as di-isononyl-67 
cyclohexane-1,2-dicarboxylate (DINCH; DEHP and DiNP replacement) and bis(2-68 
ethylhexyl) terephthalate (DEHT), a structural isomer of DEHP 18–21. However, due to their 69 
dominant use and rapid substitution, considerable levels of DINCH and DEHT have been 70 
reported in the indoor environment, raising concerns about their potential effects on humans 71 
22–25.  72 
Due to their critical and vulnerable developmental status, pre and postnatal children’s 73 
exposure to PEs via indoor dust and PVC materials has been linked with chronic respiratory 74 
problems such as allergies, asthma, bronchial hyperactivity and inflammation, as well as 75 
neurodevelopmental disorders manifesting in adulthood 26–31. Franken et al. (2017) reported 76 
the high occurrence of asthma in Belgian teenagers (especially girls) associated with high 77 
DEHP and DnBP exposure 32. DEHT and DINCH administration to rodents revealed no signs 78 
of DEHP-like toxicity 33–35. However, DINCH in utero exposure has been associated with 79 
signs of impaired liver metabolism and premature testicular aging such as  decreased 80 
testosterone secretion, physical changes in seminal glands and testicular atrophy in  rats and 81 
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their young offspring 36. Thus, the debate regarding the safety of alternative plasticisers is 82 
ongoing especially during early-life exposure. 83 
Physiologically-based extraction tests (PBET) have been employed to assess the oral 84 
bioaccessibility (i.e. uptake) of PEs via dust ingestion 37–39. PE gut bioaccessibility decreased 85 
as logKow increased; LMW PEs such as DMP and DEP were found to be 32 % and 26 % 86 
bioaccessible, respectively, while DEHP was only 10 % bioaccessible via the gut 38. In a 87 
comparative study between different dust size fractions and oral bioaccessibility, Wang et al. 88 
(2013) reported the highest gut uptake for LMW PEs in < 63 μm size fraction, compared to 89 
particles > 63 μm39. Dermal absorption of DEP and DnBP directly from air has been 90 
proposed by Weschler et al40. Since no studies exist regarding the inhalation bioaccessibility 91 
of organic pollutants, this calls for their development 41.  92 
This is the first study we are aware of quantifying the inhalation bioaccessibility of PEs and 93 
alternative plasticisers employing two artificial lung fluids, mimicking two distinctively 94 
different interstitial lung conditions. Artificial pulmonary fluids have been previously 95 
employed in inhalation bioaccessibility studies of water-soluble metals and nanoparticles 42–96 
46. Artificial lysosomal fluid (ALF, pH=4.5) represents the fluid which inhaled particles come 97 
into contact with after phagocytosis by alveolar and interstitial macrophages within the lung. 98 
Gamble’s solution (GMB, pH=7.4) is a surrogate fluid for deep dust deposition within the 99 
interstitial fluid of the lung 43,46. The objectives of the present study are to evaluate the in 100 
vitro inhalation bioaccessibility of PEs, DINCH and DEHT present in indoor dust by 101 
employing two different artificial pulmonary fluids, i.e. Gamble’s solution and ALF 102 
representing the healthy and inflammatory status of the tracheobronchial environment, 103 
respectively and to assess possible factors influencing inhalation bioaccessibility of PEs, 104 
DINCH and DEHT. 105 
Material and methods 106 
Sampling and dust particle properties 107 
Details on the A-TEAM sampling protocols  are given elsewhere47. Pre-existing vacuum 108 
cleaner dust samples (N=10) were passed through a methanol-washed, metallic sieve (< 63 109 
μm) with respect to the inhalable aerodynamic particle cut off convention according to the 110 
International Organization for Standardization (ISO)48. Specific surface area and dust particle 111 
size were determined by laser diffraction spectroscopy (Mastersizer 3000, Malvern Ltd., 112 
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UK), while total carbon (TC %) and nitrogen (TN %) contents were determined by Thermo 113 
Flash 2000 and organic matter content (OMC %) was determined by loss-on-ignition (LOI) 114 
as described elsewhere 49.  115 
Dust extraction and clean-up 116 
Details of the indoor dust extraction have been published previously 24,50. Briefly, 100 mg of 117 
dust (< 63 μm) were extracted with 10 mL acetone: n-hexane (1:1 v/v) using microwave-118 
assisted extraction (MAE) under controlled pressure and temperature. Prior to extraction, 400 119 
ng ISTD mix prepared in n-hexane (DMP-d4, DnBP-d4 and DEHP-d4) were spiked into all 120 
samples. The dust extracts were concentrated to 0.5 ml under a gentle nitrogen (N2) stream 121 
which was filtrated through a glass Pasteur pipette tip containing charcoal in order to 122 
eliminate any traces of external contamination and the solvent was exchanged to n-hexane. 123 
This solution was loaded onto an ENVI-Florisil cartridge (500 mg / 3 mL, Biotage Isolute, 124 
Uppsala, Sweden) and 9 mL of n-hexane were added as a cleaning elution step. During the 125 
second elution, all target analytes were eluted using the 9 mL acetone: n-hexane (1:1) and the 126 
resulting eluate was concentrated to 1 ml with a gentle N2 flow at room temperature, filtered 127 
as described above. Finally, all extracts were transferred to GC vials and biphenyl (300 ng) 128 
was added as an injection recovery standard prior to GC-MS/MS analysis (Fig SI 1). Further 129 
details about instrumental analysis are available in SI. 130 
Lung fluid extraction 131 
All lung fluid extractions were conducted in duplicate. Both media were freshly prepared 24 132 
h before the initiation of each test in ultra-pure H2O (18.2 Ω) as described elsewhere43 (Table 133 
SI 3), pH-adjusted using HCl 1 M and NaOH 1 M, stored at 4°C and were checked for 134 
background phthalate contamination prior use. According to Boisa et al (2014), the 135 
experimental volume for simulated lung fluid extraction tests should be equal to 20 mL, 136 
given the pulmonary fluid volume capacity of healthy non-smoking adults (0.3 mL / kg; 70 137 
kg body mass)42. In order to maintain 1:100 solid-to-liquid (S/L) ratio between the incubated 138 
matrix and the pulmonary fluid, 0.2 g of indoor dust (< 63 μm) were combined with 20 mL of 139 
each artificial lung fluid separately, as suggested by Schaider et al51. All samples were 140 
covered on top with oven-baked aluminium foil to avoid background phthalate 141 
contamination, followed by continuous incubation inside a thermostatic chamber (60 rpm; 37 142 
°C) for 96 h , a time point relevant to the human alveolar clearance capacity 45,52. After 96 h, 143 
the samples were separated by centrifugation (1500 rpm; 3 min) and the lung supernatants 144 
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were subjected to liquid-liquid extraction (LLE) using 7 mL Hexane: MTBE 3:1 twice, while 145 
ultrasonication-assisted extraction was employed for the residual dusts twice for 10 min using 146 
7 mL of Acetone: Hexane 1:1. Prior to all extractions, all samples were spiked with 400 ng 147 
ISTD mix prepared in n-hexane (DMP-d4, DnBP-d4 and DEHP-d4). To avoid any water 148 
residue and remove any gel-like emulsion formulated during LLE, sufficient amount of oven-149 
baked Na2SO4 (powder) was added to all extracts, followed by 1 min vortexing and organic 150 
phase collection after centrifugation (1500 rpm; 3 min). All extracts were combined, solvent 151 
was exchanged to n-hexane and concentrated to 1 ml under a gentle N2 stream at room 152 
temperature, filtered as described above. The residual dust extracts were subjected for clean-153 
up through ENVI-Florisil SPE cartridge (500 mg / 3 mL, Biotage Isolute, Uppsala, Sweden), 154 
similarly to the dust extraction procedure described above. Briefly, the residual dust extracts 155 
were loaded onto the Florisil® columns, the first hexane eluate was discarded, while the 156 
second eluate was collected using 9 mL of MTBE. The resulting eluate was concentrated to 1 157 
ml under a gentle N2 flow at room temperature, filtered as described above. Finally, all 158 
extracts were transferred to oven-baked GC vials and biphenyl (300 ng) was added as an 159 
injection recovery standard prior to GC-MS/MS analysis (Fig SI 2).  160 
Data analysis  161 
Inhalation bioaccessibility (IBAF) was determined using Eq. 1, where mass phthalate (lung 162 
supernatant) is set as the phthalate mass (ng) determined in the lung supernatant of the in 163 
vitro pulmonary system and mass phthalate (dust residual) is the mass (ng) determined in the 164 
dust residual collected after the 96 h-incubation of the in vitro pulmonary system which is 165 
considered as the non-bioaccessible fraction.  166 
IBAF%168 
=
𝑚𝑎𝑠𝑠 𝑝ℎ𝑡ℎ𝑎𝑙𝑎𝑡𝑒 (
𝑙𝑢𝑛𝑔 
𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
) 
𝑚𝑎𝑠𝑠 𝑝ℎ𝑡ℎ𝑎𝑙𝑎𝑡𝑒 (lung supernatant) + 𝑚𝑎𝑠𝑠 𝑝ℎ𝑡ℎ𝑎𝑙𝑎𝑡𝑒 (𝑑𝑢𝑠𝑡 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙)
 𝑥 100     (Eq. 1)  169 
 167 
GraphPad Prism® version 7.00 for Windows, (GraphPad Software, La Jolla CA, USA) was 170 
used for statistical analysis. Prior to statistical analysis, all data were checked for normality 171 
using the Shapiro–Wilk test and not all data passed the normality test. All data were arc-sine 172 
transformed, as this mathematical transformation is necessary for statistical analysis of results 173 
set in percentages in order to equalise variances among treatments 53. Ordinary two-way 174 
ANOVA (Uncorrected Fisher’s test, p<0.05) was performed to assess statistically significant 175 
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differences of target analytes between both pulmonary fluids. Spearman’s correlation 176 
(p<0.05) was employed to assess statistical dependence and correlation between artificial 177 
lung fluids and the physicochemical properties of all target analytes. 178 
Quality assurance and quality control  179 
The methods were evaluated using SRM 2585 as QC sample during dust (n=5) and lung fluid 180 
(n=4) extractions, respectively. Oven-baked, uncontaminated sand was used as a procedural 181 
blank during dust extractions; four blank lung fluid samples with no added matrix (two for 182 
each lung fluid) were sequentially incubated and analysed as procedural blanks. The results 183 
were blank-corrected for all target analytes by subtraction of the mean blank values from the 184 
raw  target analytes values (expressed in ng g-1) according to Abdhalah and Covaci54. 185 
Extraction efficiency for all target analytes ranged from 70 – 120% for both lung fluids 186 
respectively (Table SI 6). Method limits of detection (mLOD) were calculated as three times 187 
the standard deviation of the lung fluid blanks (Table SI 7).  188 
Results and discussion 189 
PEs and alternative plasticisers in indoor dust 190 
Apart from DEHT, levels of PEs and DINCH from floor (N=61) and vacuum cleaner dust 191 
(N=58) from the ATEAM cohort have been previously reported 23 and were of the same order 192 
of magnitude as reported here (N=10; SI Table xxx). Besides the smaller dust particle size 193 
used in this study compared to Giovanoulis et al.23 (< 63 μm and < 500 μm, respectively), the 194 
median values for all target analytes were marginally different apart from DINCH (this study: 195 
17.06 μg g-1, Giovanoulis et al.: 32.82 μg g-1; p<0.05). Substantial differences between the 196 
maximum values of two studies were also found, e.g. DEP (this study: 54.2 μg g-1, 197 
Giovanoulis et al: 240 μg g-1) or DiNP (this study: 2470 μg g-1, Giovanoulis et al: 1490 μg g-198 
1). These findings can be attributed to a) differences in sample size assessed and b) 199 
differences in particle size cut off  and specific surface area which are likely to influence a 200 
pollutant’s concentration in dust 39,55. However, the aim of the present study is primarily to 201 
assess the inhalation bioacceessibility of PEs and their alternatives plasticisers, rather than 202 
report on their levels in dust.  203 
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Inhalation bioaccessibility  204 
This is the first study on the in vitro inhalation bioaccessibility of PEs and alternative 205 
plasticisers via indoor dust. Inhalation bioaccessibility for DMP and DEP exceeded 70 % in 206 
both pulmonary media (Fig. 1). Statistical comparison of IBAF between the two pulmonary 207 
media did not reveal any statistically significant differences for any target analyte regarding 208 
the fluids’ pH (pH Gamble’s = 7.4; pH ALF = 4.5) and composition, apart from DMP 209 
(p=0.017) with 71 % and 82 % IBAF for Gamble’s solution and ALF, respectively. DEP was 210 
also readily absorbed with 76 % and 75 % IBAF in Gamble’s solution and ALF, respectively 211 
(p>0.05), showing thus that inhalation is an important route of exposure for LMW PEs. 212 
Gamble’s solution is representative of the interstitial fluid of the deep lung area and ALF is 213 
representative of the more acidic environment following phagocytosis by alveolar and 214 
interstitial macrophages within the lung 42,43. Hence, the inhaled dust particles would not have 215 
to be phagocytised before a considerable uptake of plasticisers occurs, with the exception of 216 
DMP.  217 
Similarly to gut bioaccessibility which is partly governed by a pollutant’s physico-chemical 218 
properties including MW and log Kow 
56,57, inhalation bioaccessibility of PEs decreased 219 
against the increasing trend in MW and log Kow (> 4). DiBP pulmonary uptake was 15.5 % 220 
and 12 %, in Gamble’s solution and ALF, respectively, whereas DnBP and HMW PEs were 221 
10 % and < 5 % bioaccessible in both media, including DEHP and its alternatives, DEHT and 222 
DINCH (Fig 1). Such findings endorse ingestion (food or dust) and dermal uptake as the 223 
predominant exposure routes for medium and HMW PEs, strongly influenced by their 224 
hydrophobic character and low water solubility 6,23,38. However, no consensus exists 225 
regarding pulmonary media composition for inhalation bioaccessibility studies of organics. 226 
Employing modified media formulations with the addition of biologically relevant pulmonary 227 
surfactants such as albumin, mucin and dipalmitoylphosphatidylcholine (DPCC) have been 228 
proposed 41,42,58; the case of DPCC makes biological sense and it should be thus 229 
systematically investigated along with other test parameters including S/L, incubation 230 
duration and particle size cut off 41,59, aiming towards a unified approach similarly to gut 231 
bioaccessibility56. 232 
Method performance using SRM 2585  233 
Method performance was assessed using SRM 2585, since the pulmonary media used here 234 
were initially designed for nanoparticle and trace element inhalation bioaccessibility 235 
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studies43,45,60. IBAF > 75 % was found for LMW PEs, while DEHP and DiNP were the least 236 
bioaccessible (IBAF < 5 %) as highly hydrophobic compounds (Table 1), following a 237 
comparable pattern to the Norwegian house dust IBAF results. The SRM 2585 batch 238 
purchased in our study was prepared using a pool of dust samples collected during mid to late 239 
1990s. Thus, DINCH and DPHP were not detected, since they were introduced in the market 240 
after 200018,61.  241 
In this study we propose an in vitro method regarding the inhalation bioaccessibility of PEs 242 
and their alternatives via indoor dust. Low MW PEs such as DMP and DEP were highly 243 
bioaccessible in both artificial pulmonary media (> 75 %), regardless of the medium’s pH 244 
and composition. Unlike DEP which presented similar pulmonary uptake in both media, 245 
DMP was more readily absorbed through ALF than Gamble’s solution. HMW PEs along with 246 
DEHP alternatives, DEHT and DINCH did not exceed 5 % pulmonary uptake. Therefore, 247 
inhalation is a considerable route of exposure for LMW and less hydrophobic PEs. The lung 248 
uptake potential for compounds with comparable physico-chemical properties, e.g. LMW 249 
polycyclic aromatic hydrocarbons (PAHs) or organophosphates (PFRs) should be further 250 
assessed. Our results show that inhalation bioaccessibility of organic pollutants is primarily 251 
governed by hydrophobicity and water solubility. Future research should be targeted towards 252 
a unified and biologically relevant in vitro pulmonary uptake test for organics relevant to dust 253 
deposition in the lung, human lung function and inflammation in vivo. Finally, animal studies 254 
are more representative of the in vivo situation, marking them as necessary for the validation 255 
of in vitro inhalation bioaccessibility tests. 256 
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Artwork and tables  273 
 274 
Figure 1 – In vitro inhalation bioaccessibility (IBAF%) of phthalate esters and alternative 275 
plasticisers present in indoor dust samples (N=10), using two different simulated lung fluids, 276 
namely Gamble’s solution (GMB) and artificial lysosomal fluid (ALF). Statistically 277 
significant differences shown here (*; p<0.05). Bar charts represent average values in 278 
duplicates. Error bars represent 1 STDEV. 279 
Table 1 - Lung fluid method performance using SRM 2585 (n=4) for Gamble’s solution and 280 
artificial lysosomal fluid (ALF)  281 
Target 
analytes† 
Gamble’s 
IBAF%  
(n=2) 
STDEV 
ALF IBAF% 
(n=2) 
STDEV 
13 
 
DMP 89.9 1.8 89.5 0.3 
DEP 80.7 1.2 73.7 1.0 
DiBP 17.6 2.7 8.0 0.6 
DnBP 9.8 1.3 6.2 0.5 
BzBP 18.5 3.6 13.2 0.6 
DEHP 3.1 1.6 2.0 0.2 
DEHT 4.9 1.6 4.6 0.6 
DiNP 3.9 1.0 3.5 0.3 
     †DINCH and DPHP not present in SRM 2585  282 
Table 2 –Spearman’s correlation between inhalation bioaccessibility (IBAF) in Gamble’s 283 
solution (GMB) and artificial lysosomal fluid (ALF) and the physicochemical properties of 284 
plasticisers studied here 285 
 GMB IBAF ALF IBAF 
Physico-chemical 
properties† 
Spearman's ρ p value Spearman's ρ p value 
MW -0.561 0.096 -0.561 0.096 
Log Kow -0.705 0.027* -0.705 0.027* 
Log Koa -0.588 0.081 -0.624 0.060 
Vapour pressure -0.535 0.115 -0.559 0.098 
Water solubility 0.661 0.044* 0.636 0.054 
*levels of statistical significance: p<0.05  286 
† Physicochemical properties of plasticisers studied here can be found at Table SI xxx 287 
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